

omadacycline (NUZYRA)

Diagnoses Considered for Coverage:

- Acute bacterial skin and skin structure infections (ABSSSI)
- Community-acquired bacterial pneumonia (CABP)

Coverage Criteria:

For diagnosis of community-acquired bacteria pneumonia (CABP), approve if:

- Patient is at least 18 years old, **and**
- One of the following:
 - Patient already started on Nuzyra, or
 - Prescribed by or in consultation with an infectious disease specialist, or
 - Inadequate response, intolerable side effect or contraindication to any of the following: amoxicillin, doxycycline, macrolide (azithromycin, clarithromycin), amoxicillin/clavulanate, or cephalosporin, AND patient is unable to use a respiratory fluoroquinolone (moxifloxacin, levofloxacin),**and**
- Dose does not exceed 600 mg per day on day 1, then 300 mg per day for up to 14 days.

For diagnosis of acute bacterial skin and skin structure infections (ABSSSI), approve if:

- Patient is at least 18 years old, **and**
- Dose does not exceed 450 mg per day x 2 days, then 300 mg per day for up to 14 days, **and**

For MRSA bacterial infection

- One of the following:
 - Prescribed by or in consultation with an infectious disease (ID) specialist, or
 - Provided C&S documenting MRSA and inadequate response, intolerable side effects, or contraindication to ONE oral antibiotic agent to which the identified organism is sensitive.

Non-MRSA bacterial infection

- Prescribed by or in consultation with an infectious disease (ID) specialist, **and**
- Inadequate response, intolerable side effects, or contraindication with TWO formulary oral antibiotic agents to which the identified

	organism is sensitive on the provided culture and sensitivity report.	
Coverage Duration: one time		

Effective Date: 6/28/2023